FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2946957219> ?p ?o ?g. }

• W2946957219 abstract "e23063 Background: Clinical symptom is often a direct method to evaluate the treatment effects. With the emergence of EGFR-targeted drugs on market, it is unclear to apply cutaneous toxicity in evaluating treatment effects and outcomes in cancer patients. This study aimed to determine whether adverse skin event as a survival indicator for patients treated with EGFR tyrosine kinase inhibitors. Methods: PubMed, EMBASE, Scopus, trial register and Cochrane Library were searched on November 11, 2018 to identify studies reporting survivals outcomes. The following search/exploded terms were used: “ EGFR-TKIs: gefitinib/erlotinib/afatinib/osimertinib ”, “ cutaneous toxicity”, “ survival”. Two investigators performed study selection independently and assessed risk of bias with ROBINS-I method. Data were pooled with random effects models and further subgroup by cancer types. Funnel plot, Egger test and Begg test were performed for detection of publication bias. Sensitivity analysis was performed by excluding potential outliers. Results: There were 24 studies identified with 4696 patients included. Skin adverse event was found to be significantly associated overall survival rate (HR, 0.48; 95% CI, 0.43-0.53; P < 0.00001; I 2 = 83%) and progression free survival rate (HR, 0.59; 95% CI, 0.41-0.85; P= 0.004; I 2 = 88%). Subgroup analysis suggested among non-small cell lung cancer patients, skin adverse event was significantly associated with overall survival (HR, 0.39; 95% CI, 0.25-0.60; P < .0001; I 2 = 86%) but not progression free survival (HR, 0.65; 95% CI, 0.29-1.45; P= 0.29; I 2 = 95%). Among other cancer types patients, skin adverse event was significantly associated with overall survival (HR, 0.59; 95% CI, 0.41-0.84; P= 0.004; I 2 = 70%) and progression free survival (HR, 0.61; 95% CI, 0.41-0.91; P= 0.02; I 2 = 80%). Begg test and Egger test suggested no evidence of publication bias. Sensitivity analysis also showed similar results. Conclusions: Skin eruption had 52% lower risk of death and 41% lower risk of progression in cancer patients treated with EGFR-TKIs. This association should be further incorporated with cancer survivorship care planning." @default.
• W2946957219 created "2019-06-07" @default.
• W2946957219 creator A5002599922 @default.
• W2946957219 creator A5010929324 @default.
• W2946957219 creator A5018607197 @default.
• W2946957219 creator A5027958721 @default.
• W2946957219 creator A5057475035 @default.
• W2946957219 creator A5065678081 @default.
• W2946957219 date "2019-05-20" @default.
• W2946957219 modified "2023-09-23" @default.
• W2946957219 title "Cutaneous eruption as a prognosis indicator for cancer patients treated with EGFR tyrosine kinase inhibitors: A systematic review and meta-analysis." @default.
• W2946957219 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e23063" @default.
• W2946957219 hasPublicationYear "2019" @default.
• W2946957219 type Work @default.
• W2946957219 sameAs 2946957219 @default.
• W2946957219 citedByCount "0" @default.
• W2946957219 crossrefType "journal-article" @default.
• W2946957219 hasAuthorship W2946957219A5002599922 @default.
• W2946957219 hasAuthorship W2946957219A5010929324 @default.
• W2946957219 hasAuthorship W2946957219A5018607197 @default.
• W2946957219 hasAuthorship W2946957219A5027958721 @default.
• W2946957219 hasAuthorship W2946957219A5057475035 @default.
• W2946957219 hasAuthorship W2946957219A5065678081 @default.
• W2946957219 hasConcept C121608353 @default.
• W2946957219 hasConcept C126322002 @default.
• W2946957219 hasConcept C143998085 @default.
• W2946957219 hasConcept C16005928 @default.
• W2946957219 hasConcept C170493617 @default.
• W2946957219 hasConcept C184235292 @default.
• W2946957219 hasConcept C2778820342 @default.
• W2946957219 hasConcept C42362537 @default.
• W2946957219 hasConcept C502942594 @default.
• W2946957219 hasConcept C54355233 @default.
• W2946957219 hasConcept C71924100 @default.
• W2946957219 hasConcept C86803240 @default.
• W2946957219 hasConcept C95190672 @default.
• W2946957219 hasConceptScore W2946957219C121608353 @default.
• W2946957219 hasConceptScore W2946957219C126322002 @default.
• W2946957219 hasConceptScore W2946957219C143998085 @default.
• W2946957219 hasConceptScore W2946957219C16005928 @default.
• W2946957219 hasConceptScore W2946957219C170493617 @default.
• W2946957219 hasConceptScore W2946957219C184235292 @default.
• W2946957219 hasConceptScore W2946957219C2778820342 @default.
• W2946957219 hasConceptScore W2946957219C42362537 @default.
• W2946957219 hasConceptScore W2946957219C502942594 @default.
• W2946957219 hasConceptScore W2946957219C54355233 @default.
• W2946957219 hasConceptScore W2946957219C71924100 @default.
• W2946957219 hasConceptScore W2946957219C86803240 @default.
• W2946957219 hasConceptScore W2946957219C95190672 @default.
• W2946957219 hasLocation W29469572191 @default.
• W2946957219 hasOpenAccess W2946957219 @default.
• W2946957219 hasPrimaryLocation W29469572191 @default.
• W2946957219 isParatext "false" @default.
• W2946957219 isRetracted "false" @default.
• W2946957219 magId "2946957219" @default.
• W2946957219 workType "article" @default.